TRANSVAC: New Vaccines Faster
TRANSVAC is a collaborative infrastructure project funded by the European Commission (EC), initially under the 7th Framework Programme (FP7) and currently under Horizon 2020. The project is a joint effort of leading European groups working in the field of vaccine development, and is coordinated by the European Vaccine Initiative (EVI). TRANSVAC is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development.
SARS-CoV-2 illustration:Centers for Disease Control and Prevention (CDC) Image by: CDC/ Alissa Eckert, MS; Dan Higgins, MAMS
Support to development of vaccines against COVID19
Researchers developing vaccine candidates against #COVID19 are encouraged to apply and benefit
from all TRANSVAC2 services, such as:
Adjuvant formulation - Vaccine Formulation Institute , Statens Serum Institut and Helmholtz Centre for Infection Research
Structural Biology - INSTRUCT
Animal models - CEA, BPRC, IRTA-CReSA and Helmholtz Centre for Infection Research
Clinical Trial Support - ECRIN (European Clinical Research Infrastructure Network)
Regulatory support - EATRIS and European Vaccine Initiative
Check out all services available here >>>>
You cannot find the services you need?
If the service you require is not among the services currently offered by TRANSVAC2, please contact EATRIS (davidmorrow@eatris.eu) and we can assess it on case by case basis.
For specific inquiries on the details of each service available please contact directly service providers
Eligibility Criteria for COVID19 applications will be less stringent.
COVID19 applications review process will be fast-tracked.
Consider this
Latest News, events & more...
